发明名称 Composition for treatment of undifferentiated gastric cancer
摘要 Disclosed are: a therapeutic agent, a kit and a treatment method for undifferentiated gastric cancer; and a pharmaceutical composition, a kit and a treatment method which are more effective on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing a mutant FGFR2. A combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on undifferentiated gastric cancer. The combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing a mutant FGFR2.;
申请公布号 US8962655(B2) 申请公布日期 2015.02.24
申请号 US200812524754 申请日期 2008.01.28
申请人 Eisai R&D Management Co., Ltd. 发明人 Yamamoto Yuji
分类号 A01N43/42;A61K31/47;C07D215/00;C07D215/22 主分类号 A01N43/42
代理机构 Fish & Richardson P.C. 代理人 Fish & Richardson P.C.
主权项 1. A method for treating undifferentiated gastric cancer, characterized by administering effective dosages of 4(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, or a pharmacologically acceptable salt thereof, and a therapeutic substance selected from the group consisting of irinotecan, paclitaxel, and pharmacologically acceptable salts thereof to a living organism.
地址 Tokyo JP